Literature DB >> 19025891

Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.

Yu Zeng1, Yoshiyuki Kakehi, Mohammed Ahmed Abdel Muneem Nouh, Hiroyuki Tsunemori, Mikio Sugimoto, Xiu-Xian Wu.   

Abstract

OBJECTIVE: To elucidate gene expression profiles of lysophosphatidic acid (LPA)-related molecules in cancer, pre-cancerous lesion, and benign hyperplasia of the prostate.
MATERIALS AND METHODS: Prostate tissue samples were surgically obtained from 10 patients with localized prostate cancer and seven patients with invasive bladder cancer. Cancer cells and the corresponding stromal cells from normal prostate, high grade intraepithelial neoplasia (HGPIN), benign hyperplastic glands were isolated by laser capture microdissection. mRNA levels of three LPA receptors, LPA1, LPA2, LPA3, two LPA-synthesizing enzymes, autotaxin (ATX), acylglycerol kinase (AGK), and a LPA-degradation enzyme, prostatic acid phosphatase (PAP), were quantitatively assessed. The expression levels of the same genes were also determined in three human prostate cancer cell lines LNCaP, PC-3, and DU-145.
RESULTS: LPA1 mRNA level was significantly decreased in HGPIN and cancer epithelia when compared to the benign glands. LPA3 mRNA level was elevated in cancer epithelia compared to benign glands. LPA3, AGK, and PAP were predominantly expressed in LNCaP cells while LPA1 and ATX gene expressions were found in PC-3 and Du-145 cells. In BPH, AGK was abundantly expressed in the stroma while PAP was predominant in epithelial cells.
CONCLUSIONS: By acting via LPA3, LPA may play an important role in the development of prostate cancer. Switching of LPA receptor expression from LPA3 to LPA1, may be involved in prostate cancer progression and/or androgen independence. LPA may also play a key role in the development of benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19025891     DOI: 10.1002/pros.20879

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  Ligand-based autotaxin pharmacophore models reflect structure-based docking results.

Authors:  Catrina D Mize; Ashley M Abbott; Samantha B Gacasan; Abby L Parrill; Daniel L Baker
Journal:  J Mol Graph Model       Date:  2011-09-18       Impact factor: 2.518

Review 2.  High-fat diet, obesity and prostate disease: the ATX-LPA axis?

Authors:  Prakash Kulkarni; Robert H Getzenberg
Journal:  Nat Clin Pract Urol       Date:  2009-02-10

3.  Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production.

Authors:  Yu Zeng; Dong Gao; John J Kim; Takumi Shiraishi; Naoki Terada; Yoshiyuki Kakehi; Chuize Kong; Robert H Getzenberg; Prakash Kulkarni
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

4.  Effects of lysophospholipids on tumor microenvironment.

Authors:  Johannes Rolin; Azzam A Maghazachi
Journal:  Cancer Microenviron       Date:  2011-09-09

5.  Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.

Authors:  Naoki Terada; Takumi Shiraishi; Yu Zeng; Steven M Mooney; David B Yeater; Leslie A Mangold; Alan W Partin; Prakash Kulkarni; Robert H Getzenberg
Journal:  Prostate       Date:  2011-10-24       Impact factor: 4.104

6.  MicroRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells.

Authors:  Suhail Ahmed Kabeer Rasheed; Cui Rong Teo; Emmanuel Jean Beillard; P Mathijs Voorhoeve; Patrick J Casey
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

7.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

Review 8.  Autotaxin.

Authors:  Jean A Boutin; Gilles Ferry
Journal:  Cell Mol Life Sci       Date:  2009-06-09       Impact factor: 9.261

Review 9.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

10.  Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.

Authors:  Xinchun Zhou; Jinghe Mao; Junmei Ai; Youping Deng; Mary R Roth; Charles Pound; Jeffrey Henegar; Ruth Welti; Steven A Bigler
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.